US FDA drops 2nd hold bomb on Idenix in wake of BMS nuke death
This article was originally published in Scrip
The US FDA's concerns about Bristol-Myers Squibb's now discontinued experimental nucleotide polymerase NS5B inhibitor BMS-094 – which has been linked, although not definitively, to heart and kidney toxicities, including one death – has taken a second toll on Idenix Pharmaceuticals' nuke program, with regulators placing a full clinical hold on the firm's next-generation NS5B IDX19368, under what the company is calling a "precautionary" measure.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.